CGNNT 总经理工作细则 版次：4 页：1/7 067-GN-P-TD-B21-124 中广核核技术发展股份有限公司 总经理工作细则 第一章 总则 第一条 为深入贯彻习近平新时代中国特色社会主义思想，把加强党的领导和完善公司治理 统一起来，深化中国特色现代企业制度建设，加快形成权责法定、权责透明、协调运转、有效 制衡的公司治理机制，提高决策效率和科学决策水平，规范中广核核技术发展股份有限公司（以 下简称"公司"）总经理及其他经营层成员依法行使职权、履行职责，根据《中华人民共和国公 司法》、《上市公司治理准则》以及《中广核核技术发展股份有限公司公司章程》（以下简称《公 司章程》）等相关规定，特制定本工作细则。 第二条 公司依据《公司章程》设置总经理一名，由董事长提名，由董事会聘任或解聘。公 司总经理对董事会负责，根据公司章程的规定或者董事会的授权行使职权。总经理列席董事会 会议。 第二章 总经理任职资格 第三条 总经理任职应当具备下列条件： （一）具有较丰富的经济理论知识、管理知识及实践经验，具有较强的经营管理能力； （二）具有调动员工积极性、建立合理的组织机构、协调各种内外关系和统揽全局的能力； （三）具有 ...

Performance Forecast - The company expects a net loss in the current reporting period, with estimated losses ranging from 90 million to 120 million yuan, compared to a loss of 86.58 million yuan in the same period last year [1] - The net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be a loss between 100 million and 130 million yuan, compared to a loss of 131.47 million yuan in the previous year [1] - Basic earnings per share are expected to be a loss between 0.0952 yuan and 0.1269 yuan, compared to a loss of 0.0916 yuan in the same period last year [1] Reasons for Performance Changes - The overall performance did not meet expectations due to several factors, despite some business segments showing positive development, such as the new materials business [1] - The expansion of the sub-therapeutic equipment market and core technology research, along with continuous investment in new isotope preparation technology, led to an increase in losses in that business segment [1] - The optical multiplier business has not yet achieved profitability due to increased R&D investment aimed at improving production line yield [1] - A decrease in the number of accelerator deliveries compared to the previous year resulted in temporary losses for that segment [1] - A reduction in government subsidies recognized in the current period also contributed to the overall losses [1]

[Estimated Performance for the Current Period](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E8%AE%A1%E6%83%85%E5%86%B5) The company projects a net loss attributable to shareholders for H1 2025, with non-recurring net loss expected to narrow compared to the prior year - The performance forecast covers the period from January 1, 2025, to June 30, 2025[2](index=2&type=chunk) Key Financial Performance Indicators | Item | Current Period (Jan 1 - Jun 30, 2025) | Prior Period | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders** | Loss: RMB 90.00 million to RMB 120.00 million | Loss: RMB 86.5778 million | | **Net Profit After Non-Recurring Items** | Loss: RMB 100.00 million to RMB 130.00 million | Loss: RMB 131.4708 million | | **Basic Earnings Per Share** | Loss: RMB 0.0952/share to RMB 0.1269/share | Loss: RMB 0.0916/share | [Communication with Accounting Firm](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%8E%E4%BC%9A%E8%AE%A1%E5%B8%88%E4%BA%8B%E5%8A%A1%E6%89%80%E6%B2%9F%E9%80%9A%E6%83%85%E5%86%B5) The performance forecast data is a preliminary estimate by the company and has not been audited by a certified public accountant - This performance forecast has not been audited by a certified public accountant[3](index=3&type=chunk) [Explanation of Performance Changes](index=1&type=section&id=%E4%B8%89%E3%80%81%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8A%A8%E5%8E%9F%E5%9B%A0%E8%AF%B4%E6%98%8E) Despite growth in new materials, overall performance fell short due to increased R&D investment in early-stage medical health and silicon photomultiplier businesses, temporary losses in accelerator operations, and a significant decrease in non-recurring government subsidies - Overall company performance fell short of expectations, primarily impacted by the following business areas: - **Medical Health Business**: Still in its early industrialization phase, current period losses expanded year-over-year due to increased investment in proton therapy equipment market expansion, core technology R&D, and isotope business layout[4](index=4&type=chunk) - **Silicon Photomultiplier Business**: In its incubation phase, it has not yet achieved profitability due to continuous investment in independent breakthroughs for critical product components and improvements in production line yield[4](index=4&type=chunk) - **Accelerator and Irradiation Business**: Due to adjustments in some client delivery schedules, the number of accelerator deliveries decreased year-over-year, resulting in a temporary loss during the reporting period[5](index=5&type=chunk) - **Non-Recurring Gains and Losses**: Government subsidies recognized in current period profit and loss significantly decreased year-over-year, leading to a substantial decline in non-recurring items compared to the prior period[5](index=5&type=chunk) [Risk Warning](index=2&type=section&id=%E5%9B%9B%E3%80%81%E9%A3%8E%E9%99%A9%E6%8F%90%E7%A4%BA) The company advises that this performance forecast is preliminary, and final financial data will be based on the officially disclosed 2025 semi-annual report, cautioning investors about investment risks - This performance forecast is a preliminary estimate, and the specific financial data will be subject to the company's upcoming 2025 semi-annual report[6](index=6&type=chunk)

Group 1 - The company China General Nuclear Power Technology (中广核技) expects a net profit loss of 90 million to 120 million yuan in the first half of 2025, compared to a loss of 86.5778 million yuan in the same period last year [1]

Core Viewpoint - The Mianyang Nuclear Medical Health Industrial Park has signed 28 projects with a total investment of 22.3 billion yuan, indicating a strong interest in the nuclear medical sector in Mianyang [4][12]. Investment and Development - Recent capital movements in the nuclear medical sector include the completion of A+ round financing by Guotong New Drug, and the listing application by Xiantong Pharmaceutical on the Hong Kong Stock Exchange [2][3]. - The Mianyang Nuclear Medical Health Industrial Park has attracted significant investment, with 28 projects signed and a total investment amounting to 223 billion yuan [4][12]. Technological Advancements - The park features advanced radiation therapy technologies, including the X-Flash and e-Flash devices, which utilize Flash radiation therapy to significantly reduce treatment time while maintaining efficacy [6][8]. - The first domestic proton therapy device is set to be produced in Mianyang, with a production base for proton equipment expected to be completed by June 2024 [9][11]. Supply Chain and Resource Availability - Mianyang has become a major supplier of medical isotopes, with a focus on the production of iodine-131 and lutetium-177, which are critical for nuclear medicine [11][24]. - The proximity of Xiantong Pharmaceutical to the isotope production base enhances supply convenience, making Mianyang an attractive location for nuclear medicine companies [11][12]. Collaborative Efforts and Government Support - The rapid development of the nuclear medical industrial park is supported by collaborations between enterprises and research institutions, as well as government initiatives [12][15]. - The local government has committed over 13 billion yuan in special bonds and guiding funds to support infrastructure and research projects in the nuclear medical sector [27]. Talent and Research Development - Mianyang has a strong talent pool, with significant investments in education and research institutions focused on nuclear science and technology [23][24]. - The establishment of key laboratories and research platforms in Mianyang aims to address critical challenges in nuclear technology applications [26].

Core Insights - The report highlights the impact of the recent US-Vietnam trade agreement on China's textile exports, with US tariffs on Vietnam reduced from 46% to 20%, potentially leading to a shift of orders from US buyers to Vietnam [8] - The outdoor industry is expected to continue thriving, supported by increasing participation in events and a growing market for outdoor products, with a target industry scale exceeding 3 trillion yuan by 2025 [9] - The real estate market is anticipated to stabilize, with potential policy support from the government, which may positively influence the home furnishing sector [10] Economic News - The National Development and Reform Commission has allocated an additional 10 billion yuan for employment projects, expected to create jobs for 310,000 individuals [2] - The People's Bank of China is exploring new measures to open the bond market to foreign investors, aiming to enhance the liquidity of RMB bonds [3] - The Hong Kong Monetary Authority plans to expand offshore RMB repurchase operations, enhancing market liquidity and supporting the development of the Hong Kong bond market [4] Company News - Shentong Express has partnered with Cainiao to advance the application of unmanned vehicles in last-mile delivery, aiming to enhance its smart delivery network [6] - Huawei has announced a new patent for an auxiliary driving method, which aims to improve drivers' perception of surrounding obstacles [6] - JD.com has launched a "Double Hundred Plan" to invest over 10 billion yuan to support quality merchants, enhancing their online sales capabilities [6] Market Review - The textile and apparel industry saw a 1.36% increase, while the light industry rose by 0.58%, indicating a positive trend in these sectors [11]

Economic News - The textile industry saw an industrial added value growth of 3.4% year-on-year from January to May 2025, with yarn, fabric, chemical fiber, and clothing production increasing by 4.9%, 0.2%, 5.5%, and 0.3% respectively [2] - The Ministry of Civil Affairs announced a special fund of 300 million yuan to support meal services for the elderly in 2025, alongside the establishment of 441,000 family elderly care beds and 798,000 home care services [2] - The Ministry of Commerce and other departments issued a work plan to promote domestic service consumption and rural revitalization, focusing on employment support and skills upgrading for domestic service workers [2] - The People's Bank of China conducted a reverse repurchase operation of 106.5 billion yuan at a rate of 1.4% [2] - The three major exchanges implemented new regulations for algorithmic trading to enhance supervision of high-frequency trading [2] - The Ministry of Civil Affairs introduced the first administrative division code management measures, effective from September 1, 2025 [2] - The National Development and Reform Commission announced that self-built high-power charging facilities by new energy vehicle companies should be open to all [2] Company Insights - Siwei Tuxin signed a contract with Beijing New Energy Automobile Co., Ltd. to develop parking software for two models, with no significant impact on the company's current financial status [6] - Bangji Technology expects a net profit of 62.5 million to 70.5 million yuan for the first half of 2025, a year-on-year increase of 166.77% to 200.91% [6] - Ankai Bus reported a total sales volume of 3,742 units for 2025, a year-on-year increase of 37.88% [6] - Weijie Chuangxin launched its second-generation L-PAMiD module, achieving significant improvements in efficiency and power consumption, and has received orders from domestic brand clients [6] - Shennong Group sold 219,000 pigs in June 2025, a year-on-year decrease of 7.52%, with total sales revenue of 385 million yuan [6] Industry Analysis - The food and beverage sector showed a revenue growth of 3.92% in 2024, with a slight increase of 2.54% in Q1 2025, indicating a weak recovery with structural opportunities [19] - The liquor industry faced a slowdown with a revenue growth of only 1.68% in Q1 2025, impacted by a negative macro environment and a ban on business-related alcohol [20] - The snack food segment experienced a revenue growth of 12.74% in 2024, but slowed to 0.29% in Q1 2025, with some products showing strong growth potential [21] - The condiment industry saw a recovery in gross margin due to lower raw material prices, with leading companies like Haitian Flavor Industry showing improved profitability [22] - The frozen food sector faced challenges with a revenue decline of 4.54% in Q1 2025, although the baking segment showed significant growth [23] - The dairy industry is expected to recover as raw milk prices stabilize, with companies like Yili and Bright Dairy showing signs of improved performance in Q1 2025 [25] Investment Recommendations - The solid-state battery industry is accelerating, with companies like Yiwei Lithium Energy and Ganfeng Lithium making significant advancements in battery technology [26][27] - The solid-state battery technology is expected to meet high-performance demands and is likely to be widely adopted in new applications such as eVTOL and humanoid robots [27] - Investment opportunities are highlighted in companies with leading solid-state battery technology and those involved in the supply chain, such as Guoxuan High-Tech and Tianan Technology [29]

致:中广核核技术发展股份有限公司 北京市君合(深圳)律师事务所(以下简称"本所")受中广核核技术发展股份 有限公司(以下简称"贵公司"或"公司")的委托,就贵公司 2024年年度股东会 (以下简称"本次股东会")召开的有关事宜,根据《中华人民共和国公司法》(以 下简称"《公司法》")、《中华人民共和国证券法》《上市公司股东会规则》(以下简 称"《股东会规则》")等中国(包括香港特别行政区、澳门特别行政区和台湾省, 为出具本法律意见书之目的,特指中国大陆地区)现行法律、法规和规范性文件(以 下简称"中国法律、法规")以及现行《中广核核技术发展股份有限公司公司章程》 (以下简称"《公司章程》"）的有关规定,出具本法律意见书。 本法律意见书仅就本次股东会的召集和召开程序、出席本次股东会人员的资格、 召集人资格、会议表决程序是否符合中国法律、法规及《公司章程》的规定以及表 决结果是否合法有效发表意见,并不对本次股东会所审议的议案内容以及该等议案 所表述的相关事实或数据的真实性、准确性或合法性发表意见。 在本法律意见书中,本所仅依据本法律意见书出具日及以前发生的事实及本所 对该事实的了解,并仅就本次股东会所涉及的相关中 ...

证券代码：000881 证券简称：中广核技 公告编号：2025-031 中广核核技术发展股份有限公司 2024 年年度股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 1.本次股东会未出现否决议案的情形。 2.本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开的日期、时间： （1）现场会议召开日期、时间：2025 年 6 月 30 日（星期一）下午 2:30； （2）网络投票日期、时间：通过深圳证券交易所交易系统进行网络投票的具 体时间为：2025 年 6 月 30 日上午 9:15 至 9:25、9:30 至 11:30、下午 1:00 至 3:00； 通过深圳证券交易所互联网投票系统投票的具体时间为 2025 年6 月 30 日上午 9:15 至下午 3:00 期间的任意时间。 2.会议召开方式：本次股东会采取现场投票与网络投票相结合的方式。 3.现场会议召开地点：深圳市福田区深南大道 2002 号中广核大厦北楼 19 层 881 会议室。 4.召集人：公司董事会。 5.主持人： ...

Core Insights - The domestic high-performance Silicon Photomultiplier (SiPM) has achieved significant breakthroughs in localization, marking a successful end to foreign monopolization in this sector [2] - SiPMs are crucial optical-electronic conversion devices with applications in nuclear medical imaging, nuclear measurement and control equipment, high-energy physics research, and biological sciences, showcasing immense potential [2] - The establishment of Zhongjing Optoelectronics by China General Nuclear Power Corporation (CGN) and Beijing Normal University aims to promote the transformation of technological achievements with proprietary technologies [2][3] Company Developments - Zhongjing Optoelectronics has successfully established a packaging production line with a device yield exceeding 90%, filling the gap in the domestic high-performance SiPM market [2] - The company invested in a high-standard cleanroom facility and designed a high-level packaging production line that integrates standardized production and quality control [3] - The production line has passed EU RoHS certification and is on track to achieve ISO certification, laying a solid foundation for large-scale application and market expansion [3] Market Strategy - The company is focused on optimizing SiPM product performance and is actively pursuing market expansion in relevant fields [3] - The goal is to build core competitiveness and self-sustaining development capabilities, contributing to the localization and autonomy of high-end equipment in China [3]